Article Text

Download PDFPDF

Comparison of Olanzapine versus Other Second-Generation Antipsychotics in the Improvement of Insight and Medication Discontinuation Rate in Schizophrenia
  1. Hongbo He1,
  2. Yanling Zhou1,
  3. Mingzhe Yang1,2,
  4. Xiongxiong Li2,
  5. Yu-Tao Xiang3 and
  6. Jiandong Luo2
  1. 1Department of Psychiatry, The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou Mental Health Center, Guangzhou, China
  2. 2Department of Pharmacology, Guangzhou Medical University, Guangzhou, China
  3. 3Unit of Psychiatry, Faculty of Health Sciences, University of Macau, Macao SAR, China
  1. correspondence: Yanling Zhou. Mailing address: 36 Mingxin RD, Liwan District, Guangzhou, China. Postcode: 510370. E-Mail: zhouylivy{at}; & Jiandong Luo. Mailing address: Xinzao, Panyu District, Guangzhou, China. Postcode: 511436. E-Mail: jiandongluo{at}


Background In the last decade, olanzapine became widely used in mental health service worldwide even after being criticized for its metabolic side effects. Patients with schizophrenia on olanzapine were usually found to stay on their medications longer than the other second-generation antipsychotics (SGAs) except clozapine. The reason for this is unknown.

Objective This prospective study compared the influences of olanzapine and other SGAs except clozapine on improving insight and medication discontinuation rate in schizophrenia.

Methods A total of 148 patients with schizophrenia medically indicated for initiation of treatment with olanzapine or other SGAs were evaluated for symptoms, insight, attitudes toward medication, side effects, body weight and fasting lipid and glucose parameters at admission and before discharge, and follow-up calls one-year after discharge documented whether they were regularly taking prescribed psychotropic medication or not.

Results After an average of 72.8 days of inpatient treatment, the olanzapine and other SGAs group exhibited similar levels of symptom improvement with an average reduction of 28.7 in the Positive and Negative Syndrome Scale (PANSS) total score. The Olanzapine group exhibited better improvement in insight assessed using the G12 item of PANSS and Insight and Treatment Attitudes Questionnaire (ITAQ), more metabolic side effects indexed with total cholesterol, triglycerides levels and weight gain, and a lower medication discontinuation rate than the other SGAs group.

Conclusion Although general symptom improvement was similar, olanzapine significantly improved insight and presented less medication discontinuation compared to other SGAs, which might partially explain why patients on olanzapine stayed longer on their medications.

  • insight
  • medication discontinuation rate
  • olanzapine
  • second-generation antipsychotics
  • schizophrenia

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.